Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 255

1.

Characterization of a new myeloid leukemia cell line with normal cytogenetics (CG-SH).

Munker R, Nordberg ML, Veillon D, Williams BJ, Roggero A, Kern W, Dicker F, Haferlach T.

Leuk Res. 2009 Oct;33(10):1405-8. doi: 10.1016/j.leukres.2009.04.008. Epub 2009 May 2.

PMID:
19414191
2.

New cytokine-dependent acute myeloid leukemia cell line MUTZ-11 with disomic chromosome rearrangement t(16;17).

Hu ZB, Quentmeier H, Meyer C, Kaufmann M, MacLeod RA, Drexler HG.

Leuk Res. 2004 May;28(5):509-15.

PMID:
15068904
3.

Trisomy 13 is strongly associated with AML1/RUNX1 mutations and increased FLT3 expression in acute myeloid leukemia.

Dicker F, Haferlach C, Kern W, Haferlach T, Schnittger S.

Blood. 2007 Aug 15;110(4):1308-16. Epub 2007 May 7.

4.

AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations.

Tang JL, Hou HA, Chen CY, Liu CY, Chou WC, Tseng MH, Huang CF, Lee FY, Liu MC, Yao M, Huang SY, Ko BS, Hsu SC, Wu SJ, Tsay W, Chen YC, Lin LI, Tien HF.

Blood. 2009 Dec 17;114(26):5352-61. doi: 10.1182/blood-2009-05-223784. Epub 2009 Oct 6.

5.

[Analysis of immunophenotype and leukemia associated immunophenotype in 610 patients with acute myeloid leukemia].

Liu YR, Wang YZ, Chen SS, Chang Y, Fu JY, Li LD, Wang H, Yu H, Jiang B, Huang XJ.

Zhonghua Xue Ye Xue Za Zhi. 2007 Nov;28(11):731-6. Chinese.

PMID:
18457262
6.
7.

Duplication of isodicentric chromosome 21, idic(21)(p11.2), leading to pentasomy 21q in acute myeloid leukemia with multilineage dysplasia.

Shimoyama M, Yamamoto K, Nishikawa S, Minagawa K, Katayama Y, Matsui T.

Cancer Genet Cytogenet. 2009 Oct;194(1):38-43. doi: 10.1016/j.cancergencyto.2009.04.019.

PMID:
19737652
8.
9.

Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML.

Dicker F, Haferlach C, Sundermann J, Wendland N, Weiss T, Kern W, Haferlach T, Schnittger S.

Leukemia. 2010 Aug;24(8):1528-32. doi: 10.1038/leu.2010.124. Epub 2010 Jun 3. No abstract available.

PMID:
20520634
10.
11.

Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.

Harada Y, Harada H.

J Cell Physiol. 2009 Jul;220(1):16-20. doi: 10.1002/jcp.21769. Review.

PMID:
19334039
12.

Prognostic implications of gene mutations in acute myeloid leukemia with normal cytogenetics.

Gaidzik V, Döhner K.

Semin Oncol. 2008 Aug;35(4):346-55. doi: 10.1053/j.seminoncol.2008.04.005. Review.

PMID:
18692685
13.

Point mutations in the AML1/RUNX1 gene associated with myelodysplastic syndrome.

Harada H, Harada Y.

Crit Rev Eukaryot Gene Expr. 2005;15(3):183-96. Review.

PMID:
16390315
14.

Characterization of CD13 and CD33 surface antigen-negative acute myeloid leukemia.

Kraguljac N, Marisavljevic D, Jankovic G, Radosevic N, Pantic M, Donfrid M, Miletic N, Boskovic D, Colovic M.

Am J Clin Pathol. 2000 Jul;114(1):29-34.

PMID:
10884796
15.

Establishment and characterization of a new, factor-independent acute myeloid leukemia line designated Ei501.

Weidmann E, Brieger J, Karakas T, Maurer U, Pascheberg U, Hoelzer D, Mitrou PS, Bergmann L.

Leukemia. 1997 May;11(5):709-13.

PMID:
9180296
16.

Comprehensive analysis of cooperative gene mutations between class I and class II in de novo acute myeloid leukemia.

Ishikawa Y, Kiyoi H, Tsujimura A, Miyawaki S, Miyazaki Y, Kuriyama K, Tomonaga M, Naoe T.

Eur J Haematol. 2009 Aug;83(2):90-8. doi: 10.1111/j.1600-0609.2009.01261.x. Epub 2009 Mar 21.

PMID:
19309322
17.

Molecular mechanisms that produce secondary MDS/AML by RUNX1/AML1 point mutations.

Harada Y, Harada H.

J Cell Biochem. 2011 Feb;112(2):425-32. doi: 10.1002/jcb.22974.

PMID:
21268063
18.

MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia.

Jongen-Lavrencic M, Sun SM, Dijkstra MK, Valk PJ, Löwenberg B.

Blood. 2008 May 15;111(10):5078-85. doi: 10.1182/blood-2008-01-133355. Epub 2008 Mar 12.

19.

Gene expression profiling of minimally differentiated acute myeloid leukemia: M0 is a distinct entity subdivided by RUNX1 mutation status.

Silva FP, Swagemakers SM, Erpelinck-Verschueren C, Wouters BJ, Delwel R, Vrieling H, van der Spek P, Valk PJ, Giphart-Gassler M.

Blood. 2009 Oct 1;114(14):3001-7. doi: 10.1182/blood-2009-03-211334. Epub 2009 Aug 7.

20.

Supplemental Content

Support Center